Therapies protein

Mohan, N. et al., Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy [abstract], Arthritis Rheum., 43 Suppl. 9, S228, 2000. 

Hayes, T. and Ryffel, B. (1997). Symposium in writing Safety considerations of recombinant protein therapy Introductory comments. Clinical Immunology and Immunotherapy 83 1-4. 

A second unanswered concern is whether the antibody induced by the recombinant protein has any discernible health effect. Other than some reports of neutralization of biological activity, little pathology has been attributed to the presence of antibodies in patients given recombinant protein therapy. It should also be noted that the question of antibody specificity has not been well studied, so that it is entirely conceivable that autoimmune pathology or even an anaphylaxis response could be induced. Equally important is the concern that induced antibody might neutralize the endogenous hormone or protein that it is intended to replace or supplement. 

Rakhmilevich, A.L., Timmins, J.G., Janssen, K., Pohlmann, E.L., Sheehy, M.J. and Yang, N.-S. (1999) Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity a direct comparison with systemic IL-12 protein therapy. J. Immunother., 22, 135-144. 

Two approaches have generally been used to achieve therapeutic angiogenesis protein therapy and gene transfer which are briefly discussed next. 

Gene and protein therapy PTP inhibition Upregulation of VEGF expression by other agents... 

Genomic information Used to identify possible protein therapies and targets, to develop biomarkers, and to understand more deeply how a given compound interacts with a complex living system. 

Examples of combination products include drug-eluting stents, implantable insulin pumps, and skin patches that deliver protein therapies. A biological product is a virus, vaccine, therapeutic serum, toxin or antitoxin, blood, blood component or derivative, or allergenic that prevents, treats, or cures diseases or injuries to humans. Biological products include viral vaccines, human blood and plasma, and interferons and erythropoietins. 

Serum samples from nonsmokers, smokers, and cancer patients (breast, colon, prostate, head, and neck) on cytotoxic and protein therapies. Aliquots of the serum samples were spiked with 6 or 60mU/mL erythropoietin. The unspiked and spiked samples were analyzed using an in house ELISA method. The basal concentration (unspiked) was subtracted from the observed concentration of each individual to obtain the corrected concentration. The % recovery was calculated against the nominal spike concentration of 6 or 60 mU/mL. 

PO. Rapid absorption, extensive metabolism. Abrupt withdrawal may induce psychosis. Potentiates antihypertensive and anticholinergic agents. Displaces drugs from plasma proteins. Therapy is withheld if granulocyte count is < 1500/mrrr. 

Brigham K L, et al. (2000). Transfection of nasal mucosa with a normal alphal-antitrypsin gene in alphal-antitrypsin-deficient subjects comparison with protein therapy. Hum. Gene Ther. 11 1023-1032. 

Bayley H. Protein therapy—delivery guaranteed. Nat Biotech 1999 17 1066-1067. 

G6PD), are less than 5% of maternal levels. Conversely, protein therapy with a stabilized form of catalase will protect against the embryopathic effects of benzo [a]pyrene and phenytoin. 

Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res 2007 67(4) 1769-1774. 

Frankel AE, Fleming DR, Powell BL et al. (2003) DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther 3 179-186... 

Antigen-antibody complex in nonspecific protein therapy Typhoid vaccine Boiled milk Diphtheria antitoxin... 

Figure 19.3 Limitations of cell and protein therapies and advantages offered by bioresorbable biomaterials for the administration of therapeutics to the heart.

In addition to the low molecular weight drugs conjugated to polymers the principle of bioconjugation can be further extended in the delivery of larger molecules such as proteins, peptides and oligonucleotides. The main drawback of biologically active protein therapy is the short body residence time due to rapid renal elimination of such molecules. Once the polymer is attached to the... 

---